Immune Complexes and Tumor-associated Proteins in Human Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Immune Complexes and Tumor-associated Proteins in Human Breast Cancer PDF full book. Access full book title Immune Complexes and Tumor-associated Proteins in Human Breast Cancer by Lawrence D. Papsidero. Download full books in PDF and EPUB format.
Author: Lawrence D. Papsidero
Publisher:
ISBN:
Category :
Languages : en
Pages : 222
Get Book Here
Book Description
Author: Lawrence D. Papsidero
Publisher:
ISBN:
Category :
Languages : en
Pages : 222
Get Book Here
Book Description
Author: Fernando Salinas
Publisher: Springer Science & Business Media
ISBN: 1468449311
Category : Medical
Languages : en
Pages : 291
Get Book Here
Book Description
Immune Complexes and Human Cancer, the fifteenth volume of Contem porary Topics in Immunobiology, is a compilation of information derived from recent studies on the role of circulating immune complexes (CIC) in the patho genic manifestations of a variety of human cancers. Technical improvements in the detection of CIC in body fluids have resulted in data that indicate that CIC do occur in different types of cancer. In addition, tumor-associated antigens and antibodies have been detected in immune complexes of cancer patients' sera. Until recently the exact role and clinical relevance of immune complexes have been the subject of debate, partially because of the problems encountered in measuring immune complexes. But these problems are being confronted as more accurate measurement protocols are developed. Technical refinements, along with strict protocols, have provided evidence of heterogeneity in CIC, a factor that makes accurate detection of immune complexes in cancer patients difficult. Recent insights indicate that the measurement of immune complexes in cancer patients may be clinically useful not only as a tumor marker, but also in regard to the deranged immune response of tumor-bearing hosts and other disorders such as nephrotic syndrome, immune anemias, and clotting dysfunction.
Author: Wei-Zen Wei
Publisher: IOS Press
ISBN: 9781586034948
Category : Medical
Languages : en
Pages : 168
Get Book Here
Book Description
In this issue, exciting new directions are outlined by fourteen groups of investigators working on critical areas in Breast Cancer Immunology. In the clinic, patients are responding to Her-2 peptides or GM-CSF transfected tumor cell vaccines. Futhermore, tumors under vaccine induced immune attack can prime the host to additional antigens. Selected chemotherapeutic agents are used to further vaccine efficacy. These promising results highlight the value of breast cancer immunotherapy. Although the clinical progress is exciting, significant challenges remain. Many tumor-associated antigens are self-antigens and vigorous measures will be required to induce consistent and sustained anti-tumor immunity. There is a pressing need for new immunotherapy targets. In this issue, the better-characterized glycoprotein antigens and novel molecules in angiogenesis are examined as new targets of breast cancer vaccines or immunotherapy. Continued effort in new antigen identification will be critical to cancer control. Finally, a reality check is warranted. Most breast cancer cells are still elusive to immune intervention.The mechanisms of such evasion are under intense investigation and much progress has been made. Alteration in antigen processing machinery is a major route of tumor evasion.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book Here
Book Description
In the present grant we propose to explore the use of genetically engineered antibodies as therapeutic agents specifically attempting to augment and potentiate the host immune defense systems against breast cancer. We will use antibodies specific for HER2/neu, a molecule present on the surface of many breast cancers; its increased expression is associated with poor prognosis. To this antibody we will join the cytokines IL-2, IL-i 2, and GM-CSF. Expression of these cytokines by cancer cells has been shown to render them immunogenic. The anti-HER2/neu will be used to localize the cytokine at the tumor where it is expected to elicit an immune response. The resulting immune response would be expected to be specific not only for the targeting antigen, but also for other tumor associated antigens resulting in the destruction of both the tumor cells which express the targeting antigen as well as those that do not. Simultaneous targeting of more than one cytokine to the tumor would be expected to lead to synergism in immune activation and an even more potent immune response.
Author: Michael R Shurin
Publisher: Springer Science & Business Media
ISBN: 9400762178
Category : Medical
Languages : en
Pages : 745
Get Book Here
Book Description
Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0
Get Book Here
Book Description
The elucidation of the immune response to cancer should be of great help in the development of new therapeutic strategies for the treatment of breast cancer. Based on recent advances in our understanding of antigen recognition by T lymphocytes, it has been possible to identify several tumor-associated antigens (TAA) recognized by CTLs. However, the expression for these TAAs has been shown to be relatively low in breast cancer tumor cells. A new protein named mammaglobin has been demonstrated to be exclusively expressed in the mammary epithelium. In addition, 90% of primary breast cancer tumors have high levels of expression of the mammaglobin protein. Given the exclusive mammaglobin expression in breast cancer tumors, this novel protein may prove to be a TAA highly specific for breast cancer that could be utilized in the near future for in vitro breast cancer-specific activation of CTLs. The discovery of mammaglobin-derived antigenic peptides that are highly expressed in breast cancer tumor tissue and are recognized by CTLs offer many exciting future therapeutic options for the treatment of breast cancer.
Author: Stephen Haskill
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 456
Get Book Here
Book Description
Author: Stuart K. Calderwood
Publisher: Springer Science & Business Media
ISBN: 1402064012
Category : Medical
Languages : en
Pages : 399
Get Book Here
Book Description
Heat shock proteins are emerging as important molecules in the development of cancer and as key targets in cancer therapy. These proteins enhance the growth of cancer cells and protect tumors from treatments such as drugs or surgery. However, new drugs have recently been developed particularly those targeting heat shock protein 90. As heat shock protein 90 functions to stabilize many of the oncogenes and growth promoting proteins in cancer cells, such drugs have broad specificity in many types of cancer cell and offer the possibility of evading the development of resistance through point mutation or use of compensatory pathways. Heat shock proteins have a further property that makes them tempting targets in cancer immunotherapy. These proteins have the ability to induce an inflammatory response when released in tumors and to carry tumor antigens to antigen presenting cells. They have thus become important components of anticancer vaccines. Overall, heat shock proteins are important new targets in molecular cancer therapy and can be approached in a number of contrasting approaches to therapy.
Author: Nima Rezaei
Publisher: Academic Press
ISBN: 0128140402
Category : Science
Languages : en
Pages : 200
Get Book Here
Book Description
Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines. - Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer - Presents the status of past and current vaccines for cancer treatment - Considers advantages and disadvantages of different therapeutic cancer vaccines - Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods - Analyzes obstacles to development of therapeutic cancer vaccines - Gives a view on future perspectives in the application of therapeutic cancer vaccines
Author: Giampietro Gasparini
Publisher: Springer Science & Business Media
ISBN: 159259915X
Category : Medical
Languages : en
Pages : 335
Get Book Here
Book Description
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
